Stay updated on PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Sign up to get notified when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.

Latest updates to the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedThe revision was updated from v3.6.3 to v3.6.4. This marks the deployment of a newer page version.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now shows revision v3.6.3, replacing the previous v3.6.2, indicating a minor update to the page's versioning information.SummaryDifference0.1%

- Check39 days agoChange DetectedA new revision tag v3.6.2 has been added and the previous v3.6.0 tag was removed, indicating an updated version of the page’s revision history.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page adds a recruitment status notice indicating no further participant enrollment and adds new help/navigation sections (How to Read a Study Record, Common Questions, How to Join a Study). It also changes the heading formatting from 'Intervention / Treatment' to 'Intervention/Treatment' and removes the 'Revision: v3.5.5' text, reflecting an updated site version.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page's revision tag was updated from v3.5.4 to v3.5.5. This indicates a new administrative refresh of the study record.SummaryDifference0.1%

- Check82 days agoChange DetectedThe study record now indicates that results have been posted and includes updated completion dates and related study documents, reflecting the PATHWay trial's final data availability. This update communicates the trial's progression to results reporting and final status to users reviewing the record.SummaryDifference3%

Stay in the know with updates to PATHWay Study: Adjuvant Pembrolizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PATHWay Study: Adjuvant Pembrolizumab Clinical Trial page.